The Medica l Innovation Achievements Translation Center of Shenzhen University is a professional service platform for the translation of medical scientific and technological achievements and innovation and entrepreneurship of Shenzhen University, which closely relies on the rich resources of the Medical Center of Shenzhen University and its affiliated hospitals. The center is characterized by the gathering of high-level medical engineering talents and outstanding figures in the medical field, is committed to promoting the technological translation of medical research results, and focuses on cultivating biomedical engineering professional and technical talents with innovative thinking and engineering practice capabilities.

Shenzhen University General Hospital (Shenzhen University School of Clinical Medical Sciences, hereinafter referred to as ‘SZU General Hospital’), fully invested by the Shenzhen Municipal People’s Government, is positioned as an internationally renowned and domestic first- class research hospital integrating medical treatment, teaching, scientific research and health management, and is the first public hospital directly affiliated with Shenzhen University. In the city’s public satisfaction survey of the healthcare industry, the hospital was ranked the first in 2019, the second in 2020, the first in 2021 and the first in 2022 in the ranking of the city’s tertiary public general hospitals for patient satisfaction assessment.

The hospital has set up 44 clinical and medical departments, 43 specialist outpatient clinics, 289 specialist disease outpatient clinics, 24 patient wards, and 19 MDT teams to meet the multi­level and diversified treatment needs of patients. The hospital is the first academician hospital in Shenzhen, with Jiang Baoguo, an academician of the Chinese Academy of Engineering, as its president. The hospital adheres to the construction of clinical centres to drive the construction of disciplines, and the radiation of dominant disciplines to drive several high- quality characteristics of the disciplinary group synergistically and concurrently. It has been approved as Shenzhen Trauma Treatment Clinical Medical Research Centre and Shenzhen Blood System Disease Clinical Medical Research Centre. The three major disciplines of spine surgery, stomatology and general surgery have been listed as key cultivation disciplines in Shenzhen. Under the guidance of the National Trauma Medical Centre, the trauma centre drives the development of the hospital’s emergency medical platform and accelerates the construction of the ‘Five Centres’ one-stop life-saving treatment system. Successfully introduced seven cities medical and health ‘three projects’ team, ‘famous doctors’ with ‘famous departments’, ‘famous departments’ to promote ‘famous’. The ‘famous doctors’ will lead the ‘famous departments’, and the ‘famous departments’ will promote the ‘famous hospital’. It has built a first-class haematopoietic stem cell transplantation centre in China and the largest one in South China. The clinical capacity in the fields of haematology, emergency trauma, spinal and orthopaedic diseases, oncology, neurological diseases, urological diseases, gastrointestinal tract, oral diseases and nursing is at the top of the provincial and municipal level and the first-class level in China.

The hospital has built a mechanism system integrating basic research, clinical research and achievement transformation. There are two municipal clinical medical research centres and one municipal key laboratory. The hospital has been awarded 278 projects, including 43 projects of the National Natural Science Foundation of China. 357 SCI papers have been published, and many high-quality research results have been published in Cell, Nature and other top international journals. Nearly 190 patents have been authorized. Relying on Shenzhen University, the hospital has cooperated to build 9 university-level research platforms. SZU General Hospital has been recruiting talents from home and abroad, and has formed a high-level and high-quality echelon of medical professionals led by academicians of the Chinese Academy of Engineering, domestic well- known experts, middle-level backbone strength and outstanding young doctors. There are 1 academician of Chinese Academy of Engineering, 1 national outstanding youth, 1 Yangtze River Scholar, 1 chief scientist of ‘973’, and 4 people enjoying the State Council’s special allowance. There are 7 directors/deputy directors of national key disciplines and clinical key specialties, and 8 directors/deputy directors of provincial key disciplines. There are more than 1,500 employees in the hospital, including 1,216 clinical staff and 470 doctors, of whom 27.8% are doctors and 34.2% are associate professionals.

he Medical Innovation Achievements Translation Center of Shenzhen University is a professional service platform for the translation of medical scientific and technological achievements and innovation and entrepreneurship of Shenzhen University, which closely relies on the rich resources of the Medical Center of Shenzhen University and its affiliated hospitals. The center is characterized by the gathering of high-level medical engineering talents and outstanding figures in the medical field, is committed to promoting the technological translation of medical research results, and focuses on cultivating biomedical engineering professional and technical talents with innovative thinking and engineering practice capabilities.

Shenzhen University General Hospital (Shenzhen University School of Clinical Medical Sciences, hereinafter referred to as ‘SZU General Hospital’), fully invested by the Shenzhen Municipal People’s Government, is positioned as an internationally renowned and domestic first- class research hospital integrating medical treatment, teaching, scientific research and health management, and is the first public hospital directly affiliated with Shenzhen University. In the city’s public satisfaction survey of the healthcare industry, the hospital was ranked the first in 2019, the second in 2020, the first in 2021 and the first in 2022 in the ranking of the city’s tertiary public general hospitals for patient satisfaction assessment.

The hospital has set up 44 clinical and medical departments, 43 specialist outpatient clinics, 289 specialist disease outpatient clinics, 24 patient wards, and 19 MDT teams to meet the multi­level and diversified treatment needs of patients. The hospital is the first academician hospital in Shenzhen, with Jiang Baoguo, an academician of the Chinese Academy of Engineering, as its president. The hospital adheres to the construction of clinical centres to drive the construction of disciplines, and the radiation of dominant disciplines to drive several high- quality characteristics of the disciplinary group synergistically and concurrently. It has been approved as Shenzhen Trauma Treatment Clinical Medical Research Centre and Shenzhen Blood System Disease Clinical Medical Research Centre. The three major disciplines of spine surgery, stomatology and general surgery have been listed as key cultivation disciplines in Shenzhen. Under the guidance of the National Trauma Medical Centre, the trauma centre drives the development of the hospital’s emergency medical platform and accelerates the construction of the ‘Five Centres’ one-stop life-saving treatment system. Successfully introduced seven cities medical and health ‘three projects’ team, ‘famous doctors’ with ‘famous departments’, ‘famous departments’ to promote ‘famous’. The ‘famous doctors’ will lead the ‘famous departments’, and the ‘famous departments’ will promote the ‘famous hospital’. It has built a first-class haematopoietic stem cell transplantation centre in China and the largest one in South China. The clinical capacity in the fields of haematology, emergency trauma, spinal and orthopaedic diseases, oncology, neurological diseases, urological diseases, gastrointestinal tract, oral diseases and nursing is at the top of the provincial and municipal level and the first-class level in China.

The hospital has built a mechanism system integrating basic research, clinical research and achievement transformation. There are two municipal clinical medical research centres and one municipal key laboratory. The hospital has been awarded 278 projects, including 43 projects of the National Natural Science Foundation of China. 357 SCI papers have been published, and many high-quality research results have been published in Cell, Nature and other top international journals. Nearly 190 patents have been authorized. Relying on Shenzhen University, the hospital has cooperated to build 9 university-level research platforms. SZU General Hospital has been recruiting talents from home and abroad, and has formed a high-level and high-quality echelon of medical professionals led by academicians of the Chinese Academy of Engineering, domestic well- known experts, middle-level backbone strength and outstanding young doctors. There are 1 academician of Chinese Academy of Engineering, 1 national outstanding youth, 1 Yangtze River Scholar, 1 chief scientist of ‘973’, and 4 people enjoying the State Council’s special allowance. There are 7 directors/deputy directors of national key disciplines and clinical key specialties, and 8 directors/deputy directors of provincial key disciplines. There are more than 1,500 employees in the hospital, including 1,216 clinical staff and 470 doctors, of whom 27.8% are doctors and 34.2% are associate professionals.

 

Zhongyi Sun, Doctor, chief physician, professor, local leading talent in Shenzhen, outstanding young medical talent in Guangdong Province. He is an internationally renowned expert in urology, andrology, reproductive medicine and plastic surgery, and is at the leading level in the country in the clinical fields of microsurgical treatment of male infertility, external genital repair, plastic reconstruction etc. He has led the development of plastic and cosmetic surgery of external genitalia as well as clinical research on premature ejaculation at the leading level in the international arena. At present, more than 20 medical device invention patents and utility model patents have been authorized, mainly focusing on the field of urology and male surgical instruments and bio­welding, among which a number of patents of urology and male surgical instruments such as testicular puncture biopsy device, VR sperm extractor and VR sexual dysfunction treatment instrument have been transformed, which has made important contributions to the technological advancement of urology and male surgery and development of the discipline. In addition, the industrialized prototype of the internationally leading multifunctional bio­welding instrument has been completed and is about to enter the clinic, which will lay the foundation of medical devices for the development of welding biology and the advancement of surgical technology.

He is now the leader of the Medical Innovation Achievements Translation Center of Shenzhen University. He leads a team that has reached an international leading level in the field of basic and clinical research in urology, male diseases and reproduction, as well as in the field of biological welding. He has published more than 50 SCI-recorded research papers in international journals as the first or corresponding author, presided over one major international cooperation project of the Chinese Ministry of Science and Technology, two National Natural Science Foundation of China and six other provincial and ministerial projects, edited two monographs, and participated in the formulation of Chinese {Guidelines on the Diagnosis and Treatment of Erectile Dysfunction in Males} . The relevant achievements have been awarded with the Chinese Clinical Medicine Award -Medical Technology Innovation Award, the second prize of Science and Technology Progress Award of the Chinese Ministry of Education and the and the third prize of Science and Technology Award of Chongqing Municipality.